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CYLD Deubiquitinates RIP1 in the TNFα-Induced
Necrosome to Facilitate Kinase Activation and
Programmed Necrosis
David M. Moquin, Thomas McQuade, Francis Ka-Ming Chan*
Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
Background: Necroptosis/programmed necrosis is initiated by a macro-molecular protein complex termed the
necrosome. Receptor interacting protein kinase 1 (RIPK1/RIP1) and RIP3 are key components of the necrosome.
TNFα is a prototypic inducer of necrosome activation, and it is widely believed that deubiquitination of RIP1 at the
TNFR-1 signaling complex precedes transition of RIP1 into the cytosol where it forms the RIP1-RIP3 necrosome.
Cylindromatosis (CYLD) is believed to promote programmed necrosis by facilitating RIP1 deubiquitination at this
membrane receptor complex.
Methodology/Principal Findings: We demonstrate that RIP1 is indeed the primary target of CYLD in TNFα-induced
programmed necrosis. We observed that CYLD does not regulate RIP1 ubiquitination at the TNF receptor. TNF and
zVAD-induced programmed necrosis was highly attenuated in CYLD-/- cells. However, in the presence of
cycloheximide or SMAC mimetics, programmed necrosis was only moderately reduced in CYLD-/- cells. Under the
latter conditions, RIP1-RIP3 necrosome formation is only delayed, but not abolished in CYLD-/- cells. We further
demonstrate that RIP1 within the NP-40 insoluble necrosome is ubiquitinated and that CYLD regulates RIP1
ubiquitination in this compartment. Hence, RIP1 ubiquitination in this late-forming complex is greatly increased in
CYLD-/- cells. Increased RIP1 ubiquitination impairs RIP1 and RIP3 phosphorylation, a signature of kinase activation.
Conclusions/Significance: Our results show that CYLD regulates RIP1 ubiquitination in the TNFα-induced
necrosome, but not in the TNFR-1 signaling complex. In cells sensitized to programmed necrosis with SMAC
mimetics, CYLD is not essential for necrosome assembly. Since SMAC mimetics induces the loss of the E3 ligases
cIAP1 and cIAP2, reduced RIP1 ubiquitination could lead to reduced requirement for CYLD to remove ubiquitin
chains from RIP1 in the TNFR-1 complex. As increased RIP1 ubiquitination in the necrosome correlates with
impaired RIP1 and RIP3 phosphorylation and function, these results suggest that CYLD controls RIP1 kinase activity
during necrosome assembly.
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Introduction
Programmed necrosis or necroptosis is a non-apoptotic form
of cell death with important functions in pathogen infections,
trauma-induced tissue injury, embryonic development and
lymphocyte homeostasis [1]. While apoptosis is an
immunologically “silent” form of cell death, the release of
“danger-associated molecular patterns (DAMPs)” from necrotic
cells promotes inflammation [2]. Despite the diametrically
opposite effects in physiology, the molecular pathways that
regulate apoptosis and programmed necrosis are intimately
related. TNF-like death cytokines induce apoptosis by
recruiting and activating caspase 8 via the adaptor FADD. The
essential programmed necrosis regulators RIP1 and RIP3 are
among the substrates of caspase 8 [3,4]. Cleavage of RIP1
and RIP3 inactivates their pro-necrotic kinase activity [5,6].
This inhibitory mechanism is critical to prevent extensive
necrosis during embryonic development [7-9], to enforce
lymphocyte homeostasis [10,11], and to dampen extensive
necrosis-induced inflammation in different tissues [12,13].
Although it is rarely observed, inhibition of programmed
necrosis can similarly result in a “switch” to apoptosis in certain
cell types [14,15].
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The necrosome is a specific and critical cytoplasmic
signaling complex for programmed necrosis, since it is not
detected when TNF stimulates NF-κB activation or apoptosis
[6,16,17]. Besides RIP1 and RIP3, the necrosome also
contains the RIP3 substrates mixed lineage kinase domain-like
(MLKL) and phosphoglycerate mutase family member 5
(Pgam5) [11,18,19]. Upon TNF stimulation, the essential
necrosome component RIP1 is recruited to the TNF receptor 1
(TNFR-1) complex. RIP1 is heavily ubiquitinated in the TNFR-1
signaling complex by the E3 ligases cIAP1 and cIAP2.
Polyubiquitinated RIP1 sterically restricts RIP1 from engaging
FADD and caspase 8 to inhibit apoptosis [20]. Hence, Smac
mimetics or IAP antagonists, which trigger proteasomal
degradation of cIAP1 and cIAP2, strongly sensitize cells to
TNF-induced apoptosis [21-23]. A similar inhibitory effect of
polyubiquitinated RIP1 on necrosome formation has recently
been proposed [24].
CYLD is a deubiquitinase and tumor suppressor that is often
mutated in tumors affecting the head, neck and skin
appendages (reviewed in 25). It was recently identified in a
genome-wide screen as a necrosis mediator [26]. RNAi-
mediated silencing of CYLD attenuates ROS production and
TNF-induced programmed necrosis [14]. Moreover, conditional
deletion of FADD in skin epidermis led to extensive necrosis
and inflammation that was rescued by crosses to mice carrying
a CYLD mutant allele lacking deubiquitinase activity [12].
Although evidence is lacking, CYLD was widely thought to
deubiquitinate RIP1 at the membrane-bound TNFR-1 complex
to control apoptosis and programmed necrosis [27-30].
However, several pieces of evidence suggest that this model is
insufficient to explain the function of CYLD in programmed
necrosis. For instance, CYLD is a caspase 8 substrate and
cleaved CYLD is rapidly degraded [31]. Since caspase 8 is not
recruited to the membrane-anchored TNFR-1 complex where
CYLD is supposed to exert its effect [32,33], caspase 8 should
not be able to cleave and inhibit CYLD at this complex.
Furthermore, in cells treated with Smac mimetics in which RIP1
ubiquitination is inhibited, TNF-induced apoptosis was still
protected by siRNA-mediated silencing of CYLD [34]. These
results raise the possibility that CYLD may not regulate
necrosis by acting as a deubiquitinase within the TNFR-1
signaling complex.
In this study we sought to determine the requirement of
CYLD deubiquitinase activity, its relevant target, and the
temporal and spatial regulation of the ubiquitination status of
this target during TNF-induced necrosis. We reveal that CYLD
deubiquitinates RIP1 to facilitate TNF-induced necrosis. In
addition, we show that CYLD functions in a distinct signaling
compartment to promote programmed necrosis. We show that
CYLD does not promote RIP1 deubiquitination within the
membrane-associated TNFR-1 complex. Instead, CYLD is
recruited to a NP-40 insoluble cytosolic compartment to
promote RIP1 deubiquitination within the RIP1-RIP3
necrosome. In the presence of SMAC mimetics or
cycloheximide, RIP1-RIP3 binding was delayed, but not
abrogated in the absence of CYLD. CYLD deficiency led to
hyper-ubiquitinated RIP1 in the necrosome and impaired
phosphorylation of RIP1 and RIP3. Hence, CYLD controls the
kinetics of RIP1-RIP3 necrosome formation and activation.
Methods
Reagents used
Antibodies used in the study were from BD Pharmingen
(A20, cIAP1/2, FADD, RIP1, β-actin and TNFR-1), Cell
Signaling (p-IκBα and total IκBα), Millipore EMD (K48 and K63-
specific ubiquitin antibodies), ProSci (RIP3), Santa Cruz
Biotechnology (caspase 8, TRAF2, CYLD) and Invitrogen
(CYLD and total ubiquitin antibody). Antibody against human
RIP3 has been described before [16]. Necrostatin-1 and zVAD-
fmk were obtained from Enzo Life Sciences. CellRox was
obtained from Invitrogen. Recombinant human and mouse TNF
were obtained from Biosource/Invitrogen. 5-(and 6-)-
chloromethyl-2’,7’-dichlorodihydrofluorescein acetyle ester
(CM-H 2DCFDA) and MitoSox were purchased from Invitrogen
and used as per manufacturer’s instructions. The Smac
mimetic LBW242 was a kind gift of D. Porter (Novartis). Small
interference RNAs used in the study are: human A20 (5’-
AGUACAAUAGGAAGGCUAAAUAAdTdA-3’, 5’-
GCAUGAGUACAAGAAAUGGCAGGAA-3’), human CYLD (5’-
CUUAUUUUUAGCAAAGGUUCUACCCUU-3’, 5’-
UUGGUUUAUUAUGACUGGAUGAACCUU-3’), mouse CYLD
(5’-GGUUUAGAGAUAAUGAUUGGAAAGA-3’, 5’-
AGUGUUGAAAGUACAAUUCUCCUGC-3’, 5’-
UGAGUAGAUAGCAGUAAAGUCCUCC-3’), human RIP1 (5’-
UGCAGUCUCUUCAACUUGAdTdT-3’, 5’-
UGCUCUUCAUUAUUCAGUUUGCUCCAC-3’), mouse RIP3
(5’-AAGAUUAACCAUAGCCUUCACCUCCCA-3’, 5’-
CCUUCGUUUCCUUUCCUCCUCUCUGUU-3’), human RIP3
(5’-UAACUUGACGCACGACAUCAGGCUGGA-3’, 5’-
GCAGUUGUAUAUGUUAACGAGCGGUCG-3’), human
TRAF2 (5’-GGACCUGGCGAUGGCUGACdTdT), human TR4
(5’-CCGGAGCUUCCCUCAUUUAdTdT-3’). Mouse RIP1
siRNA sequences have been described [15].
Tissue Culture
MEFs and L929 cells were grown in DMEM high sucrose
medium supplemented with 10% FCS, 2 mM glutamine, 100
units/ml penicillin, and 100 µg/ml streptomycin. HT-29 and
Jurkat cells were grown in McCoy’s 5A medium and RPMI1640
media, respectively, supplemented with 10% FCS, 2 mM
glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.
Stable clones of HT-29 cells were generated by transfection
using lipofectamine 2000 (Invitrogen) of CYLD-specific and
scrambled shRNAs from Thermoscientific/Open Biosystems.
Clones were selected by puromycin selection and checked for
GFP expression via flow cytometry. GFP+ clones were tested
for reduction of CYLD protein expression and used for
subsequent experiments.
Cell death assays
Wild type and CYLD-/- MEFs (kind gift from S.C. Sun [35])
were treated with 0.5-1 µg/ml cycloheximide (CHX) and 20 µM
zVAD-fmk where indicated for 1 hour prior to stimulation with
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the indicated amounts of recombinant mouse TNFα (rmTNF,
TRAIL, FasL, or staurosporine. In some instances, 5-10 µM the
Smac mimetic LBW242 was used. For FADD and caspase-8
deficient TNFR2+ Jurkat Cells [5], necrosis was induced by
addition of the indicated amounts of recombinant human TNF
(rhTNF). HT-29 cells were treated with 5-10 µM LBW242 and
20 µM zVAD-fmk for 1 hour prior to stimulation with 10-100
ng/ml rhTNF. Cell death was determined by flow cytometry with
propidium iodide staining or by CellTiter 96® AQueous One
Solution Cell Proliferation Assay (Promega).
Transfection of DNA Plasmids and siRNA
Jurkat cells were transfected with 150 nM of the indicated
siRNA. For L929 cells, 20 nM siRNA was used per transfection.
All siRNA transfections were performed using the HiPerfect
transfection reagent (Qiagen) as per manufacturer’s protocols.
Forty-eight hours later, cells were stimulated with TNF to
induce necrosis.
For DNA plasmid transfection into MEFs, 2.5 x 105 cells per
well of 12-well plate were plated the day before transfection.
Transfection was performed using the Lipofectamine LTX
transfection reagent (Invitrogen) as per manufacturer’s
protocol. CYLD deletion mutants were generated by PCR
amplification and cloning into pEGFP-C1 vector. Integrity of the
mutant clones was confirmed by sequencing.
For 293T cells, three hours prior to transfection cells were
plated at 3 x 105 cells/well of 12-well plate. Cells were
subsequently transfected with 1 μg/well (12-well plate) of the
indicated plasmid DNA using the Fugene6 or Fugene HD
transfection reagent (Roche) as per manufacturer’s protocol.
Immmunoprecipitations and Western Blots
For immunoprecipitations in MEFs, six million cells on two 10
cm tissue culture dishes were used per sample. For HT-29
cells, one plate of cells was used per sample. For Jurkat cells,
100-150 million cells were used. Cells were harvested and
lysed in either Complex II lysis buffer (150 mM NaCl, 20 mM
Tris-Cl [pH 7.5], 1% NP-40, 1 mM EDTA, 3 mM NaF, 1 mM β-
glycerophosphate, 1 mM sodium orthovanadate) or RIPA lysis
buffer (150 mM sodium chloride, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, and 50 mM Tris pH 8.0)
supplemented with 5 µM iodoacetamide, 2 µM N-
ethylmaleimide, 1X Complete protease inhibitors (Roche) and
Phosphatase inhibitor cocktail I (Sigma). For denaturing IPs,
cells were lysed in 1% SDS, 50 mM TrisCl pH7.4, 5 mM EDTA,
10 mM DTT, 15 U/ml DNase I supplemented with Complete
protease inhibitors (Roche), and phosphatase inhibitor cocktail
II (Sigma). After clearance with Sepharose 6B beads, lysates
were mixed with specific immunoprecipitation antibodies as
indicated for 4 hours to overnight at 4°C. Immune complexes
were then washed, boiled, and resolved on a 4-12% Bis-Tris
NuPAGE gel (Invitrogen). For sequential IP, the washed
immune complex was resuspended in RIPA buffer
supplemented with 6 M urea. After rotation at room
temperature for 30 minutes, lysates were diluted 10-fold in
RIPA buffer without urea and incubated with different ubiquitin
antibodies.
For differential centrifugation, cell lysates were centrifuged at
1,000g for 10 minutes. The resulting supernatants were
centrifuged at 10,000g for 10 minutes. The resulting pellet was
washed in 1 ml lysis buffer and centrifuged at 10,000g for an
additional 10 minutes yielding the P10 fraction. The
supernatant following first spin at 10,000g was transferred to a
new tube and spun at 25,000g. The resulting supernatant and
pellets were the S25 and P25 fractions.
In vitro kinase assays
The IP complexes were incubated for 30 minutes at 30°C in
kinase reaction buffer (20 mM HEPES [pH 7.5], 2 mM DTT, 1
mM NaF, 1 mM Na 3VO4, 20 mM β-glycerophosphate, 20 mM
MgCl2, 20 mM MnCl2, 1 mM EDTA, and 200-400 µM ATP)
supplemented with 10 µCi [32P] γ-ATP and 5 µM Histone H1.
Reactions were quenched by boiling in sample loading buffer.
Phosphorylation of Histone H1 was visualized by
autoradiography.
Results
CYLD promotes but is not essential for TNF-induced
programmed necrosis
Assembly of the RIP1-RIP3 necrosome is a key event in
programmed necrosis. The current model predicts that RIP1 in
the TNFR-1 complex has to be deubiquitinated before it can
engage RIP3 to form the cytosolic necrosome [36].
Polyubiquitinated RIP1 is a known substrate of CYLD [37], a
deubiquitinase that has been shown to participate in necrosis
signaling [26]. In agreement with previous results, silencing of
CYLD expression by siRNAs protected FADD-deficient Jurkat
cells from TNF-induced programmed necrosis compared with
cells transfected with the control siRNA against TRAIL-R4
(TR4) (Figure 1A). In contrast, siRNA silencing of A20, another
RIP1 deubiquitinase [38,39], enhanced rather than inhibited
TNF-induced programmed necrosis (Figure 1A). Surprisingly,
we consistently observed weaker protection by siRNA against
CYLD compared with those against RIP1 or RIP3 (Figure 1A).
This is in contrast to the expectation that CYLD is an essential
regulator of necrosis upstream of RIP1 and RIP3 activation
[29,40]. Similarly, HT-29 cells with stable knock-down (kd) of
CYLD also exhibited residual necrosis induced by TNF, zVAD
and Smac mimetics (SM) (Figure 1B).
L929 cells are widely used to study necrosis because they
undergo necrosis exclusively in response to TNF. Similar to
Jurkat and HT-29 cells, CYLD siRNAs provided partial
protection compared with RIP3 siRNA against TNF or TNF and
zVAD induced necrosis in L929 cells (Figure 1C-D). Consistent
with previous reports [15,41], siRNA-mediated silencing of
RIP1 did not protect L929 against TNF-induced or TNF and
zVAD-induced necrosis (Figure 1C-D). The molecular basis for
this RIP1-independent necrosis in L929 cells is unknown at
present. However, similar RIP1-independent necrosis has
recently been observed in cells with over-expression of RIP3
[42]. Thus, high RIP3 expression level could circumvent the
requirement for RIP1 in necrosis signaling.
The residual cell death observed in CYLD knock-down cells
was not due to insufficient inhibition of CYLD expression by the
CYLD Regulates TNFα-Induced Necrosome Activation
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siRNAs, since CYLD-/- mouse embryonic fibroblasts (MEFs)
also exhibited reduced but residual necrosis in response to
TNF and zVAD (Figure 2A), TNF, SM and zVAD (Figure 2B), or
TNF, cycloheximide (CHX) and zVAD (Figure 2C). While
necrosis was greatly reduced in TNF and zVAD treated CYLD-/-
MEFs, the inclusion of CHX or SMAC mimetics led to necrosis
of CYLD-/- MEFs at levels closer to that of wild type cells. A
comparison of the kinetics of necrosis in WT MEFs and CYLD-/-
MEFs revealed that there was a delay in the onset of necrosis
in the absence of CYLD, followed by residual necrosis that is
attenuated in magnitude (Figure 2D). The residual necrosis in
CYLD-/- MEFs was completely inhibited by the RIP1 kinase
inhibitor necrostatin-1 (Figure 2E), indicating that CYLD is not
essential for TNF- and RIP1-dependent necrosis. CYLD-/-
MEFs also exhibited moderate resistance to apoptosis induced
by TNF and CHX (Figure 2F-G). By contrast, CYLD-/- cells
responded normally to apoptosis induced by TRAIL, FasL or
staurosporine (Figure 2H-J). Hence, while CYLD has a
significant role in TNF and zVAD induced necrosis, it plays only
an auxiliary role to promote TNF and zVAD-induced necrosis in
the presence of SM or CHX.
CYLD does not control RIP1 ubiquitination within the
TNFR-1 complex
These results led us to re-evaluate the role of CYLD in
programmed necrosis. RIP1 recruited to TNFR-1 was heavily
ubiquitinated (Figure 3A). Although CYLD was recruited to
TNFR-1 in a ligand-dependent manner (Figure 3A, compare
lanes 1, 3 and 5), RIP1 ubiquitination was not affected in
CYLD-/- MEFs (Figure 3B, compare lanes 3-6).
Polyubiquitinated RIP1 within the TNFR-1 signaling complex is
important for assembly and activation of the IKK complex.
Consistent with the normal RIP1 ubiquitination status, IκBα
phosphorylation and degradation was normal in CYLD-/- MEFs
(Figure 3C). The normal TNFR-1 associated RIP1
ubiquitination in CYLD-/- cells was not due to compensatory
effect of another RIP1 deubiquitinase A20 that was recruited to
the TNFR-1 complex (Figure 3A, lane 5), since A20 siRNA
enhanced rather than decreased TNF-induced necrosis (Figure
1A).
Deubiquitination of RIP1 by CYLD facilitates
programmed necrosis
Certain deubiquitinases, such as A20, have been shown to
regulate cell signaling independent of their enzymatic activity
Figure 1.  Partial protection against TNF-induced necrosis by CYLD siRNAs.  (A) FADD-deficient Jurkat cells were transiently
transfected with the indicated siRNAs. Forty-eight hours post-transfection, the cells were treated with TNF to induce necrosis. The
percentage cell death was determined by propidium iodide staining and flow cytometry. Western Blots on the right show the
efficiency of gene silencing. Representative of three experiments. (B) HT-29 cells were stably transfected with either non-specific
shRNA (control) or CYLD targeting shRNA (clones: G11-2 and G11-8). Cells were treated with TNF, LBW242 and zVAD-fmk. Cell
viability was determined by MTS assay (Promega). Western blot shows that expression of CYLD was inhibited in the two selected
clones, G11 #2 and G11 #8. Representative of three experiments. (C-D) L929 cells were transfected with the indicated siRNAs.
Necrosis was induced with (C) TNF or (D) TNF and zVAD-fmk. Cell death was determined by MTS assay. The panel on the right
shows the reduction in protein expression of the siRNA transfected cells. Representative of two experiments.
doi: 10.1371/journal.pone.0076841.g001
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Figure 2.  RIP1-dependent necrosis occurs in CYLD-/- MEFs.  Wild type (CYLD+/+) and CYLD-/- MEFs were treated with (A) TNF
and zVAD, (B) TNF, Smac mimetic and zVAD, or (C) TNF, cycloheximide (CHX) and zVAD-fmk for 12 hours. Cell death was
determined by staining with propidium iodide (PI) and analyzed via flow cytometry. The inset shows loss of CYLD expression in
CYLD-/- MEFs using a C-terminal specific CYLD antibody. In (D), cells were treated with 10 ng/ml TNF, CHX and zVAD-fmk and cell
death was measured at the indicated times following treatment. Representative of three experiments. (E) Nec-1 inhibited TNF-
induced necrosis in CYLD-/- MEFs. Representative of two experiments. (F) CYLD+/+ and CYLD-/- MEFs were treated with TNF and
CHX for 12 hours. Cell death was determined by PI staining and flow cytometry. Representative of three experiments. (G) MEFs
were treated with 10 ng/ml TNF and CHX for the indicated times. Representative of two experiments. (H-J) MEFs were treated with
(H) TRAIL, (I) FasL or (J) staurosporine (STS) for 12 hours. Cell death was determined by PI exclusion and flow cytometry.
doi: 10.1371/journal.pone.0076841.g002
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[39]. Because RIP1 ubiquitination in the TNFR-1 complex was
normal in CYLD-/- cells, we asked if CYLD similarly regulates
programmed necrosis independent of its deubiquitinase
activity. We found that expression of GFP-tagged wild type
CYLD, but not the deubiquitinase inactive mutant C601S,
enhanced TNF-induced programmed necrosis in CYLD-/- MEFs
(Fig. 4A-C). Truncation mutants lacking the carboxyl terminal
ubiquitin specific protease (USP) domain also failed to restore
programmed necrosis in CYLD-/- MEFs (Figure 4C). By
contrast, the first and second CAP-Glycine (CG1 and CG2)
domains were dispensable for programmed necrosis (Figure
4C). The negative values in percentage change in cell death in
certain mutants were due to proliferation of the transfected
populations. Hence, the deubiquitinase function of CYLD is
required to promote TNF-induced programmed necrosis.
Since the deubiquitinase function of CYLD is required for
programmed necrosis and yet RIP1 ubiquitination within the
TNFR-1 complex was normal in CYLD-/- cells, we asked if RIP1
is indeed the major substrate of CYLD during programmed
necrosis. Expression of the RIP1 mutant K377R inhibited TNF-
dependent RIP1 poly-ubiquitination in the TNFR-1 complex
(Figure 4D) [43,44]. RIP1-deficient Jurkat cells reconstituted
with wild type RIP1 were protected from TNF-induced necrosis
by siRNAs against RIP1, RIP3 and CYLD (Figure 4E).
Strikingly, unlike cells expressing wild type RIP1, cells that
express the K377R mutant were not protected from TNF-
induced necrosis by CYLD siRNA (Figure 4E compare left and
right graphs). In contrast, RIP3 siRNA reduced programmed
necrosis in these cells (Figure 4E). Hence, we conclude that
RIP1 is indeed the major substrate of CYLD in programmed
necrosis.
CYLD regulates RIP1 ubiquitination in a spatially and
temporally distinct compartment
Since RIP1 is the major substrate of CYLD and yet RIP1
ubiquitination within the TNFR-1 signaling complex was not
affected in CYLD-/- cells, we assessed the possibility that CYLD
might regulate RIP1 ubiquitination in a different signaling
compartment. We prepared cell lysates by boiling in 1% SDS.
This method allows us to remove most of the RIP1 binding
proteins prior to RIP1 immunoprecipitation. Using this method,
we detected RIP1 polyubiquitination in a TNF-dependent
manner in both wild type and CYLD-/- cells (Figure 5A). These
modifications were detected several hours after TNF
stimulation when RIP1 has already been dissociated from the
TNFR-1 signaling complex (Figure 3B). In contrast to RIP1
recruited to the TNFR-1 signaling complex, RIP1 isolated from
CYLD-/- cells using this method exhibited higher levels of
ubiquitination than wild type cells at all time points examined
(Figure 5A). Moreover, the length of the polyubiquitinated
species was longer in the CYLD-/- cells compared with that in
wild type cells. Similar results were obtained in HT29 cells with
stable expression of shRNA against CYLD (Figure 5B). Hence,
RIP1 was indeed hyper-ubiquitinated in CYLD-/- cells after
dissolution of the TNFR-1 complex.
Ubiquitin-like modifications of RIP1 and RIP3 were
previously detected in the late-forming cytosolic necrosome
[16]. This suggests that CYLD might regulate RIP1
ubiquitination within the necrosome. To ascertain this
possibility, we performed sequential immunoprecipitation, first
with RIP3, followed by denaturation in urea and
immunoprecipitation with different ubiquitin antibodies.
Consistent with our previous observations [45], the RIP1-RIP3
necrosome was stable in urea. Although the different ubiquitin
antibodies exhibited differential efficiency in
immunoprecipitation, we found that RIP1 within the necrosome
Figure 3.  CYLD does not regulate RIP1 ubiquitination within the TNFR1 complex.  (A) Recruitment of CYLD and A20 to the
TNFR-1 complex. TNFR1 complex was purified from TNF, zVAD and CHX treated cells by immunoprecipitation (IP). The
recruitment of RIP1, CYLD and A20 was assessed via Western Blot. Control IPs with isotype-matched IgG were included to show
the specificity of binding to TNFR-1. (B) CYLD+/+ and CYLD-/- MEFs were treated with TNF for the indicated times. Recruitment of
polyubiquitinated RIP1 to TNFR-1 was determined by Western Blot. (C) IκBα phosphorylation and degradation was normal in
CYLD-/- MEFs.
doi: 10.1371/journal.pone.0076841.g003
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was indeed modified by ubiquitination via K48 and K63
linkages (Figure 5C). To determine the role of CYLD in
necrosome ubiquitination, we performed differential detergent
lysis, first with NP-40, followed by extraction of the NP-40
insoluble materials with SDS. RIP1 ubiquitination was reduced
in CYLD-/- cells compared with wild-type cells in the NP-40
fractions (Figure 5D, compare lanes 3 and 4, 5 and 6, and 7
and 8). In contrast, in the NP-40 insoluble, SDS-soluble
fraction, RIP1 was hyper-ubiquitinated in CYLD-/- cells (Figure
5D, compare lanes 3-4 and 5-6). Because the necrosome
preferentially accumulates in NP-40 insoluble compartment
[45], these results suggest that CYLD regulates RIP1
ubiquitination after necrosome assembly.
CYLD controls the kinetics of necrosome formation and
activation
We next examined the consequence of this hyper-
ubiquitinated form of RIP1 in necrosis signaling. Surprisingly,
Figure 4.  Poly-ubiquitinated RIP1 is the major substrate for CYLD in TNF-induced necrosis.  (A) Schematic diagram of wild-
type CYLD and deletion mutants used in the experiments. (B-C) CYLD-/- MEFs were transiently transfected with the indicated GFP-
tagged CYLD. Necrosis was induced with TNF, CHX and zVAD-fmk. Cell death was determined in the GFP+ population by PI
staining and flow cytometry. The panel on the right of (C) shows that the GFP-tagged CYLD mutants were of the correct sizes. (D)
RIP1-deficient Jurkat cells reconstituted with wild type RIP1 or RIP1-K377R were stimulated with TNF. The recruitment of RIP1 to
TNFR-1 was determined by Western blot. (E) RIP1-deficient Jurkat cells stably expressing either WT RIP1-GFP or (F) RIP1-K377R-
GFP mutant were transfected with the indicated siRNAs. Necrosis was induced with TNF and zVAD-fmk. Cell death was determined
as described before [48]. The Western blots provide validation of siRNA knock-down efficiency.
doi: 10.1371/journal.pone.0076841.g004
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we found that the assembly of the RIP1-RIP3 necrosome was
delayed, but not abolished in CYLD-/- MEFs (Figure 6A, lanes
5-8). Similar observations were made in CYLD knock-down
HT-29 cells (Figure 6B, compare lanes 3 and 4, 5 and 6, and 7
and 8). Consistent with the requirement of CYLD for TNF-
induced apoptosis (Figure 2), recruitment of RIP1 and FADD to
Figure 5.  CYLD regulates RIP1 ubiquitination in the necrosome.  (A-B) Increased RIP1 ubiquitination in the absence of CYLD.
(A) CYLD+/+ and CYLD-/- MEFs or (B) control and CYLD knock-down HT29 cells were treated with TNF, the Smac mimetic LBW242
[35] and zVAD-fmk for the indicated times. Total lysis in 1% SDS was performed as described in the methods. The level of RIP1
ubiquitination was examined by Western Blot. NS: non-specific band. (C) Necrosome-associated RIP1 contains ubiquitin chains of
different linkage types. Cells were treated with TNF and zVAD-fmk for 3 hours or left untreated. RIP3 immune complexes were
denatured in urea, followed by immunoprecipitation with the indicated antibodies against ubiquitin. (D) Selective accumulation of
poly-ubiquitinated proteins in RIP1 complexes in the NP-40 insoluble compartment. WT MEFs or CYLD-/- MEFs were treated to
undergo necrosis with TNF, zVAD-fmk, and CHX for the indicated times. Cells were lysed in NP-40 lysis buffer and insoluble
material was solubilized with SDS. RIP1 was immunoprecipitated from both fractions followed by Western blot with the indicated
antibodies.
doi: 10.1371/journal.pone.0076841.g005
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caspase-8 was similarly delayed in CYLD knock-down HT29
cells (Figure 6C, compare lanes 5 and 7, 9 and 11, and 13 and
15). Similarly, association between RIP1 and FADD was
delayed in CYLD knock-down HT-29 cells (Figure 6D, compare
lanes 2 and 8), but caught up to control cells at later time-
points (Figure 6D, compare lanes 3-5 with lanes 9-11). Nec-1
blocked the association between RIP1 and FADD in both cell-
types demonstrating that RIP1 kinase activity is required for
complex formation as previously reported (Figure 6D, compare
lanes 6 and 12). Thus, CYLD promotes, but is not essential for
assembly of the RIP1-RIP3 necrosome.
Sequential detergent extraction with NP-40 and SDS
confirmed that RIP1 and especially RIP3 accumulated in the
NP-40 insoluble, SDS fraction in a TNF-dependent manner
(Figure 7A, bottom panels). Active, phosphorylated RIP1 and
RIP3 as indicated by mobility shift were detected in the NP-40
insoluble SDS fraction as early as 2 hours post stimulation in
wild type cells (Figure 7A, lanes 3). By contrast, appearance of
phospho-RIP1 and phospho-RIP3 was not apparent until 4
hours post-stimulation in CYLD-/- cells (Figure 7A, lane 6). The
delayed phosphorylation of RIP1 and especially RIP3 was even
more apparent in CYLD knock-down HT29 cells (Figure 7B,
lanes 5-10).
The preferential phosphorylation in the SDS fraction
suggests that the kinase activity of the necrosome was
activated in this compartment. Because SDS inhibited RIP1
and RIP3 kinase activity in vitro (data not shown), we used
differential centrifugation to separate the NP-40 insoluble
fraction to determine its kinase activity (Figure 8A). We
confirmed that similar to the differential detergent lysis, the
insoluble pellet fractions obtained with this method exhibited
ligand-dependent accumulation of the necrosome components
RIP1, RIP3 and CYLD (Figure 8B, compare lanes 5-8 and
9-12). Although TNF-induced RIP1-RIP3 necrosome was
detected in both NP-40 soluble and insoluble fractions (Figure
8C, second panel, lanes 3-4, 7-8 and 11-12), TNF-induced and
RIP1-associated kinase activity was detected only in the NP-40
insoluble fractions (Figure 8C, top panel, lanes 5-8 and 9-12).
By contrast, although the necrosome was formed and low level
of kinase activity was detected in the NP-40 soluble S25
Figure 6.  CYLD regulates the kinetics of RIP1-RIP3 necrosome assembly.  (A) WT or CYLD-/- MEFs were treated with TNF,
LBW242 and zVAD-fmk for the indicated times. Recruitment of RIP1 to RIP3 was determined by Western Blot. (B) HT-29 cells
expressing non-specific shRNA (NS) or CYLD shRNA were treated with TNF, LBW242 and zVAD-fmk. RIP3 complexes were
immunoprecipitated and RIP1 association was determined by Western Blot. (C) HT-29 cells were treated with TNF, the SM LBW242
and zVAD-fmk. Caspase-8 complexes were immunoprecipitated, and recruitment of RIP1 and FADD was determined by Western
blot. (D) HT-29 cells were treated with TNF, Smac mimetic and zVAD-fmk. FADD complexes were immunoprecipitated, and
recruitment of RIP1 was determined by Western blot.
doi: 10.1371/journal.pone.0076841.g006
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fraction, TNF did not further increase this kinase activity (Figure
8C, top panel, lanes 1-4). The observed kinase activity was
partly attributed to RIP1, as it was partially inhibited by Nec-1
(Figure 8D, compare lanes 3-4). In addition to kinase activity,
we observed that RIP1-associated ubiquitination was strongly
induced in the NP-40 insoluble compartments (Figure 8E).
Paradoxically, the increase in RIP1-associated ubiquitination
correlated with the recruitment of CYLD to RIP1 (Figure 8C,
bottom panels). Inducible ubiquitination was not detected in the
soluble fractions. Collectively, these results strongly suggest
that RIP1 polyubiquitination within the necrosome critically
regulates RIP1 kinase activation.
CYLD also controls downstream ROS production
The fact that the RIP1-RIP3 necrosome could form with only
delayed kinetics and yet cell death was reduced in CYLD-/-
MEFs suggests that CYLD may also control a downstream step
in programmed necrosis. Reactive oxygen species (ROS)
production is a hallmark of necrosis. Indeed, we found that
ROS production as measured by flow cytometry or by confocal
microscopy was reduced in CYLD-/- MEFs (Figure 9A-B).
Therefore, despite relatively normal assembly of the
necrosome, CYLD-/- cells were defective for downstream
signaling such as ROS production.
Discussion
Protein ubiquitination plays key roles in cell death and innate
immune signaling pathways [46]. Polyubiquitinated RIP1 at the
TNFR-1 complex was shown to sterically hinder binding of
caspase 8 to inhibit apoptosis [20]. A similar role for
polyubiquitinated RIP1 has been proposed to inhibit necrosome
formation [24,30]. Hence, CYLD was thought to promote
necrosis by de-ubiquitination of RIP1 at the TNFR-1 membrane
complex. In contrast to this prevailing model, we show that
although CYLD was recruited to the TNFR-1 complex, RIP1
ubiquitination at the TNFR-1 complex was unaffected in CYLD-/-
cells. Moreover, the RIP1-RIP3 necrosome was formed, albeit
with delayed kinetics, in CYLD-/- or CYLD knock-down cells.
CYLD was recruited to the necrosome in a TNF-dependent
manner. However, this interaction is likely to be indirect, as
expression of CYLD in 293T cells or in baculovirus did not
reveal a strong interaction between CYLD and RIP1 (data not
shown). Adaptors such as the recently reported CLIPR-59 may
mediate the interaction between RIP1 and CYLD [47].
In contrast to RIP1 ubiquitination in the TNFR-1 complex,
RIP1 ubiquitination in the necrosome was indeed increased in
the absence of CYLD. In particular, the necrosome isolated
from the NP-40 insoluble fraction showed strong induction of
ubiquitination in response to TNF, suggesting that CYLD may
instead regulate RIP1 ubiquitination in this compartment
(Figure 10). This model is consistent with the recent discovery
that caspase 8-mediated cleavage of CYLD limits TNF-induced
programmed necrosis [24], since caspase 8 is present in the
necrosome, but not the TNFR-1 complex. Because CYLD is
not essential for necrosome assembly, but rather facilitates its
activation, our results may also explain why genetic inactivation
or siRNA silencing of CYLD was not as effective as inactivating
RIP1 or RIP3 in blocking programmed necrosis in cells or in
FADD-/- or caspase 8-/- mice [12,13].
Figure 7.  Impaired RIP1 and RIP3 phosphorylation in the absence of CYLD.  (A) MEFs were treated with TNF, zVAD-fmk and
the LBW242. Cell lysates were extracted by sequential detergent lysis in NP-40 and SDS as described in methods. RIP1 and RIP3
in each fraction were examined by Western blot. Note that phosphorylated RIP1 and RIP3 (p-RIP1 and p-RIP3) were exclusively
detected in the SDS fractions. (B) HT-29 cells stably expressing non-specific (NS) shRNA or CYLD shRNA were treated with TNF,
LBW242 and zVAD-fmk for the indicated times. Unmodified and phospho-RIP1 and phospho-RIP3 were analyzed by Western Blot.
doi: 10.1371/journal.pone.0076841.g007
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A consequence of increased RIP1 ubiquitination in CYLD-/-
cells is impaired RIP1 and RIP3 phosphorylation and
activation. The polyubiquitin chains on RIP1 may sterically
prevent autophosphorylation of RIP1 or limit access of an
upstream RIP1 activating kinase. Alternatively, it may sterically
restrict RHIM-mediated amyloid complex assembly, which
facilitates kinase activation [45]. Regardless of the mechanism,
it is surprising that CYLD deficiency led to a substantial
reduction in necrosis and yet necrosome assembly was only
marginally affected. The precise reason for this difference is
unknown at present. However, it is noteworthy that the levels of
RIP1, RIP3 and CYLD in the NP-40 fractions decreased as
programmed necrosis ensued (Figure 7). While some of the
loss could be attributed to relocation of these factors to the
Figure 8.  Induction of RIP1 associated kinase activity in the NP-40 insoluble compartment.  (A) Schematic flowchart showing
the procedures by which the different NP-40 soluble and insoluble fractions were obtained. (B) Accumulation of necrosis signaling
adaptors in the NP-40 insoluble fractions. The indicated fractions were analyzed for levels of RIP1, RIP3 and CYLD in response to
necrosis induction by TNF. β-actin was used as internal control. (C) The kinase activity of the necrosome is selectively activated in
the NP-40 insoluble fractions. Cell lysates were subjected to differential centrifugation as described in (A). The RIP1 immune
complexes were subjected to in vitro kinase assays using histone H1 as substrate. RIP1 ubiquitination and recruitment of RIP3 and
CYLD were determined by Western blot (lower panels). (D) Induction of kinase activity in the NP-40 insoluble fraction is partially
dependent on RIP1 kinase activity. The P10 fractions were prepared and RIP1 immune complexes were isolated. Where indicated,
30 µM of Nec-1 was added to the in vitro kinase assay. (E) Densitometry quantification of RIP1 ubiquitination in the different
fractions in (C).
doi: 10.1371/journal.pone.0076841.g008
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Figure 9.  ROS production is reduced in CYLD-/- MEFs.  (A)
CYLD-/- or CYLD+/+ MEFs were stimulated with TNF and zVAD
for the indicated times. ROS generation was determined by
staining with CM-H 2DCFDA as per manufacturer’s instructions.
Results shown are average +/- SEM of triplicates. (B) CYLD-/-
or CYLD+/+ MEFs were stimulated with TNF and zVAD. ROS
production was determined by staining with MitoSox as per
manufacturer’s instructions.
doi: 10.1371/journal.pone.0076841.g009
NP-40 insoluble fractions, direct lysis with SDS buffer revealed
that protein degradation might also contribute to their loss
(Figure 6A). This necrosis-induced degradation of signaling
adaptors was impaired in CYLD-/- cells. Moreover, ROS
production was also impaired in CYLD-/- MEFs. These results
suggest that CYLD may have dual functions in controlling RIP1
ubiquitination at the necrosome as well as a yet to be identified
downstream event in the necrosis signaling pathway.
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Figure 10.  Schematic diagram of the proposed mechanism of CYLD-mediated necrosis.  Although CYLD is recruited to the
TNFR-1 complex, it dose not deubiquitinate RIP1 within the this compartment. Upon transition to the cytosol, CYLD deubiquitinates
RIP1 within the NP-40 insoluble fraction to actively promote necrosome phosphorylation and activation. In addition to regulating
RIP1 ubiquitination in the necrosome, CYLD also controls downstream events of necrosis such as ROS production.
doi: 10.1371/journal.pone.0076841.g010
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